E, P.A., S, A.F., Trejeeve, M., Martha, G., Mazen, H., S, M.M., & Parag, G. (2026). Screening Strategies for Identification of Transthyretin Amyloid Cardiomyopathy.. JACC. Heart failure.
E PA, S AF, Trejeeve M, Martha G, Mazen H, S MM, et al. Screening Strategies for Identification of Transthyretin Amyloid Cardiomyopathy.. JACC. Heart failure. 2026; PMID: 41893375
E PA, S AF, Trejeeve M, et al. Screening Strategies for Identification of Transthyretin Amyloid Cardiomyopathy.[J]. JACC. Heart failure. 2026.
@article{e2026,
author = {Peters Anthony E and Ahmad Faraz S and Martyn Trejeeve and Grogan Martha and Hanna Mazen and Maurer Mathew S and Goyal Parag},
title = {Screening Strategies for Identification of Transthyretin Amyloid Cardiomyopathy.},
journal = {JACC. Heart failure},
year = {2026},
note = {PMID: 41893375},
}
TY - JOUR AU - Peters Anthony E AU - Ahmad Faraz S AU - Martyn Trejeeve AU - Grogan Martha AU - Hanna Mazen AU - Maurer Mathew S AU - Goyal Parag TI - Screening Strategies for Identification of Transthyretin Amyloid Cardiomyopathy. T2 - JACC. Heart failure PY - 2026 AN - PMID:41893375 ER -
Transthyretin amyloid cardiomyopathy (ATTR-CM) remains underdiagnosed relative to population estimates in at-risk populations. Efforts have identified clinical features that identify risk for the diagnosis of ATTR-CM and have developed associated risk prediction models to identify risk of the presence of clinical ATTR-CM disease. Prospective validation and broad implementation of these data across health care systems have been limited. In this context, there is an unmet need to synthesize existing risk modeling published reports and discuss implementation approaches to identifying ATTR-CM. In this review, we summarize results from risk prediction efforts to date, identify remaining gaps in evidence, and describe potential opportunistic health system strategies to integrate systematic ATTR-CM risk prediction and screening.